How Long Can Cord Blood & Tissue Be Stored?

This common question comes up often when researching cord blood banking. Why do some banks only offer, 18, 20 or 25 years when other banks offer lifetime banking? Here’s what we know: Cord blood is rich in hematopoietic stem cells (HSCs). These cord blood stem cells produce the cellular ingredients necessary for the blood and the immune system and are crucial for transplants. When stem cells are stored, they are done so in a cryopreserved frozen state. The question often asked is, “how long can the stem and progenitor cells be maintained in frozen form and still be viable when they are thawed?” According to Dr. Hal Broxmeyer, “the key to cord blood banking is to properly cryopreserve the stem cells so that when they are thawed for therapy they are still alive and maintain the functional capacity of the cells to repopulate the blood cells in a patient’s body.” In 2010, “Dr. Hal Broxmeyer, the scientist who invented the standard protocols for banking cord blood, stated in the journal Cell Stem Cell that his lab has thawed cord blood that was cryopreserved more than 23 years and found the recovery of viable stem cells undimished by time. “ In August 2017, a recent report from, evaluated the recovery of stem cells. Results showed that for up to 23.5 years there was a highly efficient recovery (80%- 100%). This is the longest time that cord blood has been frozen and thawed with efficient recovery of stem cells in a l...
Source: Cord Blood News - Category: Perinatology & Neonatology Authors: Tags: Cord Blood medical research stem cells Source Type: blogs

Related Links:

Publication date: Available online 8 October 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Ram Vasudevan Nampoothiri, Shiyi Chen, Ivan Pasic, Zeyad Al-Shaibani, Wilson Lam, Fotios V. Michelis, Dennis Dong Hwan Kim, Auro Viswabandya, Armin Gerbitz, Jeffrey Howard Lipton, Rajat Kumar, Jonas Mattsson, Arjun Datt Law
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
ConclusionSOS is relatively rare; therefore, a holistic approach to the patients ’ needs considering nursing role as essential may result in better care outcomes.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Publication date: December 2020Source: Journal of Chemical Neuroanatomy, Volume 110Author(s): Maryam Sadat Jalali, Alireza Sarkaki, Yaghoub Farbood, Seyed saeed Azandeh, Esrafil Mansouri, Mohammad Ghasemi Dehcheshmeh, Ghasem Saki
Source: Journal of Chemical Neuroanatomy - Category: Neuroscience Source Type: research
We report a rare case of HBV reactivation in a patient with HCV infection after DAA therapy. Patient concerns: In 1996, a 53-year-old female was identified as infected with HCV at a medical check-up, following which she visited our hospital. She was infected with HCV genotype 2b, and at follow up in 1997, was found to be hepatitis B surface antigen (HBsAg) and antibody against HBsAg negative, antibody against HBV core positive. She then experienced malignant lymphoma in 2001 at 58 years of age. Complete remission was achieved following chemotherapy and autologous peripheral blood stem cell transplantation. In 2014, she ...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
BONE MARROW TRANSPLANTATION (BMT) also called haematopoietic stem cell transplant (HSCT) is the treatment of choice for many haematological diseases including haematological malignancies and different types of anaemia1. The number of HSCT is increasing every year, mainly because of advanced research that has allowed an expansion in the number of indications for which it has become the first-line therapy2. The long-term survival of patients that have undergone BMT continues to improve with several advances in transplantation techniques and supportive care practices.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Chronic graft-versus-host disease (cGvHD) is a severe complication of allogeneic hematopoietic stem cell transplantation that affects various organs leading to a reduced quality of life. The condition often requires enduring immunosuppressive therapy, which can also lead to the development of severe side effects. Several approaches including small molecule inhibitors, antibodies, cytokines, and cellular therapies are now being developed for the treatment of cGvHD, and some of these therapies have been or are currently tested in clinical trials. In this review, we discuss these emerging therapies with particular emphasis on...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Epstein –Barr virus (EBV) is associated with the pathogenesis of a variety of malignancies, most notably lymphomas. Especially in the background of immunodeficiency, such as primary immunodeficiency disorder (P...
Source: Diagnostic Pathology - Category: Pathology Authors: Tags: Case Report Source Type: research
ConclusionIn this review, we attempted to provide a historical overview of bone marrow history, MSC discovery, characterization, and the first clinical studies conducted.
Source: International Orthopaedics - Category: Orthopaedics Source Type: research
Conclusion: Our results suggest that children who develop ARF during engraftment have better ICU survival rates than do those with other etiologies of ARF post-HSCT. Furthermore, fluid overload contributes to mortality in these children; therefore, strategies to prevent and address fluid overload should be considered.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Hematopoietic Stem Cell Transplantation Intervention:   Procedure: Hematopoietic stem cell transplantation Sponsor:   IRCCS Burlo Garofolo Completed
Source: - Category: Research Source Type: clinical trials
More News: Laboratory Medicine | Perinatology & Neonatology | Research | Stem Cell Therapy | Stem Cells | Transplants